Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Krabatsch, T; Netuka, I; Schmitto, JD; Zimpfer, D; Garbade, J; Rao, V; Morshuis, M; Beyersdorf, F; Marasco, S; Damme, L; Pya, Y.
Heartmate 3 fully magnetically levitated left ventricular assist device for the treatment of advanced heart failure -1 year results from the Ce mark trial.
J Cardiothorac Surg. 2017; 12(1):23
Doi: 10.1186/s13019-017-0587-3
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-authors Med Uni Graz
- Zimpfer Daniel
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- BACKGROUND: The HeartMate 3 Left Ventricular Assist System (LVAS) (St. Jude Medical Inc., St Paul, MN) with full magnetic levitation allows for wide and consistent blood flow paths and an artificial pulse designed for enhanced hemocompatibility. The HeartMate 3 received market approval in the European Union in 2015 following completion of a multicenter study. After reaching the 6-month study endpoint, patients continue to be followed for 2 years with the 1-year results presented herein. METHODS: A prospective, non-randomized study included adults with advanced heart failure and ejection fraction (EF) ≤ 25%, cardiac index (CI) ≤ 2.2 L/min/m2 while not on inotropes, or inotrope dependent, or on optimal medical management for 45/60 days. RESULTS: Fifty patients-54% bridge to transplant (BTT) and 46% destination therapy (DT)-were enrolled and implanted with the HeartMate 3. At baseline, 92% of the patients were INTERMACS profiles 2-4, with cardiac index 1.8 + 0.5 L/min/m2 and 58% were supported with inotropes. At 1 year, 74% of the patients remain on support, 18% expired, 6% transplanted, and 2% explanted. The adverse events include 12% gastrointestinal bleeding, 16% driveline infections, 18% strokes, and 2% outflow graft thrombosis. There was no hemolysis, pump thrombosis or pump malfunction through 1 year. The six-minute walk test distance increased from a mean of 273 m to 371 m (P <0.0001). EQ-5D quality-of-life score increased from a mean of 52.7 to 70.8 (P = 0.0006). CONCLUSIONS: The 1-year HeartMate 3 LVAS results show survival and adverse-event profile are similar to other approved devices, with no pump thrombosis or pump failure. Patient's functional status and quality of life significantly improved over time. TRIAL REGISTRATION: Clinicaltrials.gov registration number: NCT02170363 . Registered June 19, 2014.
- Find related publications in this database (using NLM MeSH Indexing)
- Equipment Design - administration & dosage
- Female - administration & dosage
- Follow-Up Studies - administration & dosage
- Heart Failure - physiopathology, therapy
- Heart-Assist Devices - administration & dosage
- Hemodynamics - physiology
- Humans - administration & dosage
- Magnets - administration & dosage
- Male - administration & dosage
- Middle Aged - administration & dosage
- Prospective Studies - administration & dosage
- Quality of Life - administration & dosage
- Time Factors - administration & dosage
- Treatment Outcome - administration & dosage
- Find related publications in this database (Keywords)
- HeartMate 3
- Magnetic levitation
- Heart failure
- LVAS